Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 17M | 16M | 39M | 61M |
| Gross Profit | -152K | 6M | 8M | 31M | 48M |
| Operating Income | -25M | -37M | -94M | -83M | 13M |
| EBITDA | -35M | -36M | -90M | -79M | 10M |
| Net Income | -23M | -38M | -93M | -84M | 7M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$2.95
-1.34% today
1Y Change
-51.61%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Veru Inc. (VERU) is a Healthcare stock with a market cap of $40.00M and listed on NASDAQ. The stock last traded around $2.95 and down 51.6% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +61.8%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +61.8%, free cash flow -37.6% with operating margin -8065.1% and ROIC -48.4%. Valuation already assumes a fairly strong business story at price/sales 146.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VERU price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VERU
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VERU Max Drawdown
-70.14%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VERU and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$61.3M
+55.7% YoY
FY Net Income
$7.4M
+108.8% YoY
Free Cash Flow
-$15.9M
+66.9% YoY
Revenue Growth
-100.0%
EPS Growth
+61.8%
Gross Margin
-46.7%
Net Margin
-7736.3%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 17M | 16M | 39M | 61M |
| Gross Profit | -152K | 6M | 8M | 31M | 48M |
| Operating Income | -25M | -37M | -94M | -83M | 13M |
| EBITDA | -35M | -36M | -90M | -79M | 10M |
| Net Income | -23M | -38M | -93M | -84M | 7M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 16M | 25M | 10M | 80M | 122M |
| Total Assets | 30M | 60M | 50M | 135M | 178M |
| Total Liabilities | 12M | 28M | 30M | 53M | 26M |
| Shareholder Equity | 18M | 32M | 20M | 83M | 152M |
| Total Debt | 3M | 14M | 14M | 16M | 14M |
| Net Debt | -13M | -11M | 5M | -64M | -109M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
16M
+67.2% YoY
Capital Expenditures
377K
+48.6% YoY
Free Cash Flow
16M
+66.9% YoY
Key ratios
Gross Margin
-46.7%
Operating Margin
-8065.1%
Net Margin
-7736.3%
ROE
-83.2%
Debt / Equity
0.08x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.